Oligosarcomas, IDH-mutant are distinct and aggressive.

Area of Science:

• Neuro-oncology
• Molecular Pathology
• Cancer Genomics

Background:

• Oligodendrogliomas are defined by IDH mutation and 1p/19q codeletion.
• Previous reports suggested gliomas with sarcomatous features arising from oligodendrogliomas (oligosarcomas).

Purpose of the Study:

• To characterize oligosarcomas as a distinct molecular and clinical entity.
• To differentiate oligosarcomas from conventional oligodendrogliomas.

Main Methods:

• Analysis of 24 oligosarcomas from 23 patients, including histology, DNA methylation profiling, copy number analysis, and proteomic profiling.
• Panel sequencing for mutations in key oncogenes and tumor suppressors.
• Comparison with conventional CNS WHO grade 3 oligodendrogliomas.

Main Results:

• Oligosarcomas form a distinct methylation class, often arising from prior oligodendrogliomas.
• Histologic and molecular features include sarcomatous changes, p53 accumulation, smooth muscle differentiation markers, altered H3K27me3, and frequent NF1/TP53 mutations.
• Loss of 1p/19q codeletion occurred in some cases via copy number neutral LOH.
• Oligosarcomas showed increased copy number variation, CDKN2A/B deletions, and aberrant YAP1 expression.
• Patient survival was significantly poorer compared to grade 3 oligodendrogliomas.

Conclusions:

• Oligosarcomas are a distinct IDH-mutant glioma group with unique histologic, epigenetic, proteomic, molecular, and clinical characteristics.
• Diagnosis can be aided by sarcomatous histology, IDH-mutation, TERT promoter mutation, and/or 1p/19q codeletion, or DNA methylation profiling.
• These findings establish oligosarcomas as a separate entity requiring specific diagnostic and therapeutic considerations.